The interest in the potential of antibody-drug conjugates (ADC) continues to grow among some of pharma’s biggest players. Bristol Myers Squibb (BMS) announced Thursday morning that it has entered into ...
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or "Company"), a clinical-stage biotechnology company, announced that it has signed an Exclusive License Agreement with ...
License agreement centered around development of a single ADC program Usage of Synaffix GlycoConnect®, HydraSpace® and toxSYN® ADC technologies to enhance efficacy, tolerability and target engagement ...
AMSTERDAM, Jan. 9, 2025 /PRNewswire/ -- Synaffix B.V. ("Synaffix"), a Lonza company (SWX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback